2-(2,5-二氯-苯基)-苯并噁唑-5-胺 | 293737-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(2,5-二氯-苯基)-苯并噁唑-5-胺
• 英文名称: 2-(2,5-dichlorophenyl)benzo[d]oxazol-5-amine
• 英文别名: 2-(2,5-Dichlorophenyl)-1,3-benzoxazol-5-amine
• CAS: 293737-84-5
• 化学式: C₁₃H₈Cl₂N₂O
• mdl: MFCD00579120
• 分子量: 279.125
• InChiKey: CEBMGSOURCAPDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(2,5-二氯-苯基)-苯并噁唑-5-胺 、 异丁酰氯 在 吡啶 作用下， 反应 18.0h， 以58%的产率得到N-(2-(2,5-dichlorophenyl)benzo[d]oxazol-5-yl)isobutyramide
  参考文献：
  名称：

  Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy

  摘要：

  A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.

  DOI：

  10.1021/jm200135z
• 作为产物：
  描述：

  2,4-二氨基苯酚 、 2,5-二氯苯甲酸 在 polyphosphoric acid 作用下， 反应 16.0h， 以66%的产率得到2-(2,5-二氯-苯基)-苯并噁唑-5-胺
  参考文献：
  名称：

  Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy

  摘要：

  A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.

  DOI：

  10.1021/jm200135z

文献信息

• Psyllid Attractants and Their Uses
  申请人：INSCENT, INC.

  公开号：US20130287727A1

  公开（公告）日：2013-10-31

  The present specification discloses psyllid attractants, compositions comprising such attractants, lures, traps and other devices using such attractants, methods and uses to attract, capture and/or kill psyllids using such attractants, compositions and/or lures, traps and/or other devices, and methods and uses for monitoring a psyllid population using such attractants, compositions and/or lures, traps and/or other devices.
• [EN] PSYLLID ATTRACTANTS AND THEIR USES<br/>[FR] ATTRACTEURS DE PSYLLES ET LEURS UTILISATIONS
  申请人：INSCENT INC

  公开号：WO2013163454A2

  公开（公告）日：2013-10-31

  The present specification discloses psyllid attractants, compositions comprising such attractants, lures, traps and other devices using such attractants, methods and uses to attract, capture and/or kill psyllids using such attractants, compositions and/or lures, traps and/or other devices, and methods and uses for monitoring a psyllid population using such attractants, compositions and/or lures, traps and/or other devices.
• Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy
  作者：Daniel R. Chancellor、Kay E. Davies、Olivier De Moor、Colin R. Dorgan、Peter D. Johnson、Adam G. Lambert、Daniel Lawrence、Cristina Lecci、Carole Maillol、Penny J. Middleton、Gary Nugent、Séverine D. Poignant、Allyson C. Potter、Paul D. Price、Richard J. Pye、Richard Storer、Jonathon M. Tinsley、Renate van Well、Richard Vickers、Julia Vile、Fraser J. Wilkes、Francis X. Wilson、Stephen P. Wren、Graham M. Wynne

  DOI：10.1021/jm200135z

  日期：2011.5.12

  A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.